Tanvex Filed Response To Amgen's Lawsuit

Recently, Tanvex BioPharma, Inc., and its wholly owned subsidiaries, Tanvex Biologics Corporation and Tanvex BioPharma USA, Inc., filed a response to Amgen’s complaint for patent infringement in the United States District Court for the Southern District of California. Tanvex’s response included defenses and counterclaims of noninfringement and invalidity.

As background, on July 23, 2019, Amgen filed lawsuit against Tanvex in the United States alleging infringement of U.S. Patent No. 9,856,287 (the ‘287 patent) based on Tanvex’s submission of a Biologics License Application (BLA) for TX01 to the United States Food and Drug Administration. TX01 is a proposed biosimilar to Neupogen (filgrastim).

About Tanvex
Tanvex BioPharma, Inc. is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan.